Ginkgo Bioworks
Ginkgo Bioworks raises $1.5B PIPE at $15B valuation
Quick Facts
Ginkgo Bioworks: PIPE Funding Round
Ginkgo Bioworks has successfully raised $1.5B in PIPE funding, reaching a valuation of $15B.
Company Overview
Synthetic biology and organism engineering platform
Funding Details
The PIPE round was led by Cathay Innovation, with participation from Baillie Gifford, Counterpoint Global, General Atlantic, Sumitomo Chemical, Viking Global, Cascade Investment.
Company Information
- Headquarters: 27 Drydock Avenue, Boston, MA 02210
- Founded: 2008
- Employees: 700+
- Category: Biotech
Investment
Ginkgo Bioworks plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Cathay Innovation: Verified investor in PIPE
- Baillie Gifford: Verified investor in PIPE
- Counterpoint Global: Verified investor in PIPE
- General Atlantic: Verified investor in PIPE
- Sumitomo Chemical: Verified investor in PIPE
- Viking Global: Verified investor in PIPE
- Cascade Investment: Verified investor in PIPE
Key Investors
About the Author
Related Company Reports
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza